These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 7799046)

  • 21. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial.
    Kaplan LD; Kahn JO; Crowe S; Northfelt D; Neville P; Grossberg H; Abrams DI; Tracey J; Mills J; Volberding PA
    J Clin Oncol; 1991 Jun; 9(6):929-40. PubMed ID: 2033429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E
    J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
    McCaffrey JA; Mazumdar M; Bajorin DF; Bosl GJ; Vlamis V; Motzer RJ
    J Clin Oncol; 1997 Jul; 15(7):2559-63. PubMed ID: 9215825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
    J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.
    Hovgaard D; Nissen NI
    Leuk Lymphoma; 1992 Jun; 7(3):217-24. PubMed ID: 1477649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancer.
    Bokemeyer C; Schmoll HJ; Metzner B; Beyer J; Illiger HJ; Kneba M; Ostermann H; Kynast B; Räth U; Poliwoda H
    Ann Hematol; 1993 Aug; 67(2):75-9. PubMed ID: 8347733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
    Engelhard M; Gerhartz H; Brittinger G; Engert A; Fuchs R; Geiseler B; Gerhartz D; Haunauske AR; Hartlapp HJ; Huhn D
    Ann Oncol; 1994; 5 Suppl 2():123-5. PubMed ID: 7515644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study.
    Walther J; Wilmanns W; Gerhartz HH
    Ann Hematol; 1993 Mar; 66(3):135-7. PubMed ID: 8471659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Rüther U; Metzner B; Illiger HJ; Clemm C; Siegert W; Link H; Ostermann H; Schmoll HJ
    Semin Oncol; 1994 Dec; 21(6 Suppl 16):57-63. PubMed ID: 7801148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.
    Beyer J; Schwella N; Zingsem J; Strohscheer I; Schwaner I; Oettle H; Serke S; Huhn D; Stieger W
    J Clin Oncol; 1995 Jun; 13(6):1328-35. PubMed ID: 7538556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
    Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
    J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human granulocyte-macrophage colony-stimulating factor in acquired or chemotherapy-induced neutropenia. An open clinical trial.
    Piguet D; Chapuis B
    Acta Oncol; 1994; 33(6):639-43. PubMed ID: 7946441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.
    Moore MJ; Iscoe N; Tannock IF
    J Urol; 1993 Oct; 150(4):1131-4. PubMed ID: 8371371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.